The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface

Withdrawn before enrolling

Conditions studied: Open Angle Glaucoma, Ocular Hypertension

In brief

This study is designed with the intention to further elucidate the effects of omega-3 fatty acids on intraocular pressure (IOP) and signs/symptoms of dry eye. Prior studies have shown statistically significant lowering of IOP with use of omega-3 fatty acids but have only been performed in animal models. This study will be the first to attempt replication in human models. A limited number of studies have shown an increase in tear production/volume as well as a decrease in the subjective symptoms of dry eye, but more studies are needed to better define these effects. Better understanding of the effects of this supplement on intraocular pressure and dry eye will contribute to the expanding knowledge about the pathophysiology of glaucoma/ocular hypertension and dry eye syndrome and potentially lead to further studies about new potential treatment options for these conditions.

Key facts

Study ID

NCT02295358

Run by

University of Colorado, Denver

People needed

0

Starts

2014-11-01

Expected to finish

2015-11-01

Last updated by the study team

2015-07-09

Who can join

Age: 40 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Ocular Hypertension or Open Angle Glaucoma of mild to moderate severity, with or without previously diagnosed dry eye syndrome, who are currently on monotherapy with a prostaglandin analog.
• Age 40-89 of either gender, of any race/ethnicity

You may not qualify if…

• Females who are currently pregnant or planning to become pregnant during the study period
• Age <40 years old
• Diagnosis of any other form of glaucoma other than open-angle
• Patients with known hypersensitivity (i.e., anaphylactic reaction) to omega-3 fatty acids or any of its components
• Patients with cirrhosis or with known liver disease
• Patients with diagnosed celiac disease
• Patients with a hypersensitivity to fish or shellfish
• Patients with paroxysmal or persistent atrial fibrillation
• Patients who are currently using medical or recreational marijuana
• Patients currently on any anticoagulation therapy including warfarin, dabigatran, apixaban, rivaroxaban, clopidogrel, cilostazol, dipyridamole, prasugrel, ticlopidine, ticagrelor
• Patients currently on Lovaza, an omega- 3 fatty acid supplement requiring a prescription
• Patients with any recent ocular surgery or laser treatment within 3 months

Where it is running

• University of Colorado Eye Center — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.